Patient Trend and History - LDL-C Level, Medications, and Initiatives

Input your patient's (Px) information in the table below. LDL values are in mg/dL.

Input dates of check-up with Px
Input LDL-C level per check-up
Input target LDL-C for Px

To determine your patient's target LDL-C, use the risk estimator tool here.

Import your patient's information to generate chart.

SUMMARY

Your LDL-C Target

Is your LDL-C on target?

Refer to the tables below for expected LDL-C lowering of different lipid lowering therapies and combinations.

Other interventions

Current Medications

Input all LDL lowering medications1 of the patient below (total daily dose).

Projected reduction is based on 6-8 weeks of medication adherence.

Select other interventions by the patient.

ACS 2025
ESC EAS Guidelines 2025

EXPECTED LDL CHOLESTEROL REDUCTION

PATIENT TYPE STATIN TOLERANT STATIN INTOLERANCE
Achievable Reductions ≥60% ≥80% ≥35% ≥60%
Potential Combinations Rosuvastatin 20-40 + Ezetimibe 10 Rosuvastatin 20-40 + Alirocumab/Evolocumab (+Ezetimibe 10) Ezetimibe 10 + Bile acids
Atorvastatin 40-80 + Ezetimibe 10 Atorvastatin 40-80 + Alirocumab/Evolocumab (+Ezetimibe 10) Ezetimibe 10 + Alirocumab/Evolocumab
Rosuvastatin 40-80 + Ezetimibe 10
Atorvastatin 10-20 + Alirocumab/Evolocumab
Rosuvastatin 10-20 + Inclisiran Rosuvastatin 20-40 + Inclisiran (+Ezetimibe 10) Bempedoic acid 180+ Ezetimibe 10
Atorvastatin 10-20 + Inclisiran Rosuvastatin 20-40 + Inclisiran (+Ezetimibe 10) Bempedoic acid 180+ Ezetimibe 10+ Evolocumab, Alirocumab or Inclisiran
Atorvastatin 20+ Ezetimibe 10+ Bempedoic acid 180 Ezetimibe 10+ Inclisiran
References:
  1. Medicine for High Cholesterol. Food And Drug Administration Philippines website. https://verification.fda.gov.ph/med_high_cholesterollist.php?start=141. Last accessed September 2025.
  2. Ray, K. K., Ference, B. A., Séverin, T., Blom, D., Nicholls, S. J., Shiba, M. H., … Santos, R. D. (2022). World Heart Federation Cholesterol Roadmap 2022. Global Heart, 17(1), 75. https://doi.org/10.5334/gh.1154
  3. Kumbhani DJ, Cibotti-Sun M, Moore MM. 2025 Acute Coronary Syndromes Guideline-at-a-Glance. J Am Coll Cardiol. 2025 Jun 10;85(22):2128-2134. doi: 10.1016/j.jacc.2025.01.018. Epub 2025 Feb 27. PMID: 40013745.
  4. Mach F, Koskinas KC, Roeters van Lennep JE, Tokgözoğlu L, Badimon L, Baigent C, Benn M, Binder CJ, Catapano AL, De Backer GG, Delgado V, Fabin N, Ference BA, Graham IM, Landmesser U, Laufs U, Mihaylova B, Nordestgaard BG, Richter DJ, Sabatine MS; ESC/EAS Scientific Document Group. 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias. Eur Heart J. 2025 Aug 29:ehaf190. doi: 10.1093/eurheartj/ehaf190. Epub ahead of print. PMID: 40878289.

For Healthcare Professionals only.

The content hosted on this platform is intended for non-promotional scientific purposes only and the content of the site is accurate at the time of publication.

Any data about non-Novartis products are based on publicly available information.

Novartis cannot make individual patient treatment recommendations. A treatment decision has to be made by the treating physician on a case-by-case basis after careful evaluation of the associated benefits and risks.

For the purposes of these independent education activities, best efforts were undertaken to ensure compliance with the PHAP code, however, you should review your local prescribing information and consult directly with Novartis Healthcare Philippines, Inc. to address any questions

Prescribing information may vary depending on local health authority approval in each country. Before prescribing any product, always refer to the Summary of Product Characteristics (SmPC) or product information approved in your local country.